Publications | Grants | Patents | Clinical trials | Companies
This Resolute Research Report assesses the current state of micelle nanoparticle development and the recent growth within the field. All tables, graphs and heat maps were generated using ResoluteAI’s discovery engine, Foundation.
Micelle nanoparticles are small particles conceived around the notion that membranes can confine their contents away from the surrounding environment. When this framework is applied to drug delivery and therapeutics, the design of these particles exists at the intersection of materials chemistry, biophysics, and biology. The modular nature of micelle nanoparticles has allowed scientists to engineer biocompatible molecules with a wide breadth of applications. An analysis of recent news reports demonstrates an increase in activity in this subject area. At the end of 2021, there was nearly a three-fold increase in news publications related to micelle nanoparticles.
Recent news activity relating to micelle nanoparticles from July 2020 - February 2022
First, we’ll explore metadata about academic publications related to micelle nanoparticles. Using Foundation from ResoluteAI, publication subject tags are applied to recently published articles. Displayed in the heat map are the top ten subjects related to the field of micelle nanoparticle research. Notably, there has been a significant increase in micelle nanoparticle research within pharmaceutical science during the past five years. This is likely due to the promise of using these particles as customizable drug delivery mechanisms.
Heatmap displaying the number of publications including "micelle" and "nanoparticle" by publication subject
In order to dive deeper into the area of micelle nanoparticles and pharmaceuticals, a tag of “drug delivery” was applied before creating this graph. The knowledge graph demonstrates current areas of research related to micelle nanoparticles. This provides insight into the possible customizations that are being researched in construction of these particles. Specifically, particle size and polymer composition appear to be large areas of research.
Network graph of MeSH descriptors associated with micelle nanoparticle publications
Funding allocated to this area of research has been steady over the past five years. Since 2018, 30 grants have been awarded to nanoparticle micelle research. During that time, the agency contributing the largest number of grants towards nanoparticle micelle research was the National Cancer Institute. This aligns with recently published news articles that describe the potential for applications to cancer treatment and diagnostics.
Grant agencies and recipients supporting research on nanoparticle micelles from 2018-present
Patent generation is a strong indicator of potential field growth. Micelle nanoparticle drug delivery patent activity has been very consistent over the past ten years. Due to the potential for customization of these layered nanoparticles, applications to drug delivery techniques are quite broad, as can be seen on the heat map generated by ResoluteAI.
Publications tagged with "Drug Delivery" within the area of micelle nanoparticle development
Clinical trials in this field are still somewhat limited. A particularly promising trial yielded significant attention from the news last year. In November of 2021, a clinical trial led by OncoNano Medicine, Inc. began evaluating the function of fluorescent nanoparticle micelles in cancer diagnostics. Besides this trial, seven other clinical trials in this field have taken place within the last ten years.
Companies Working with Micelle Nanoparticles
Softmat is a research and education service-based company. It provides a multidisciplinary soft matter bio-nanotechnology team that studies interactions of lipid membranes with nano-objects including nanoparticles, nanotubes, polymers, polymeric micelles and polymer therapeutic complexes and conjugates.
MegaPro Biomedical positions itself as a technology company with nanoparticles and nano-micelle as the core technology. This company focuses on adding value to the pre-clinical testing realm of drug research. By collaborating with pharmaceutical companies to develop drugs, MegaPro Biomedical contributes to the biomedical industry in Taiwan.
NanoCarrier Co is a pharmaceutical company that researches and develops medical products by applying the micellar nanoparticle technology. The company was founded on June 14, 1996, and is headquartered in Chiba, Japan, with a presence in Tokyo.
Research within the area of micelle nanoparticles has been growing over the past five years and has offered various opportunities relating to drug development, therapeutics, and diagnostics. Due to the modular nature of these nanoparticles, the range of research is quite broad and has shown the potential for a large variety in its application. Growth within this field has been largely focused on drug development and molecular engineering of novel drug delivery and release methods. Numerous companies have sprung up around this area of research and are exploring their own specific applications. The large capacity for customization of these nanoparticles allows for companies to examine very different areas of research.
For more information on ResoluteAI’s research and analytical tools, please contact us at email@example.com or drop us a line using the link below.